Company intelligence / Profile preview

Vaxxas

Brisbane/Hamilton* (*HQ), Queensland, Australiavaxxas.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Vaxxas has demonstrated its HD-MAP needle-free vaccine delivery system can generate robust immune responses at lower doses compared to traditional injections. The company has completed five successful Phase I clinical trials with over 500 participants using COVID‑19, flu, and measles/rubella vaccines. Its first US IND-enabled trial for a pre-pandemic flu vaccine began in late 2024 with BARDA funding. Early results show potential for improved immunogenicity and easier distribution due to thermostability.

Therapeutic areas: Infectious Diseases
Modalities: Vaccines (various types, including mRNA and protein-based)Needle-free vaccine delivery (HD-MAP technology)Microarray patch technology
Industry: Biotech

Drug pipeline

15 assets

Vaccine Enhancement Patch

14 more assets in the full pipeline.

Request access →

Partnerships

Merck/MSDUnited States Biomedical Advanced Research and Development Authority (BARDA)World Health Organization (WHO)Coalition for Epidemic Preparedness Innovations (CEPI)Gates FoundationEndpoints Capital investment partnershipUniversity of Queensland/UniQuest spinout origins.

Beyond the preview

Go deeper on Vaxxas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxxas.

Explore the full profile